Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension

Hypertension

Volumn 53, Issue 6, 2009, Pages 1091-1097

  Wolk, Robert ^a   Smith, William B ^b   Neutel, Joel M ^c   Rubino, John ^d   Xuan, Dawei ^a   Mancuso, James ^a   Gilbert, James ^a   Pressler, Milton L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Volunteer Research Group   (United States)

^c Orange County Research Center   (United States)

^d Triangle Medical Research   (United States)

Author keywords

ABPM; Blood pressure; Cgmp; Hypertension; PDE 5 inhibition; PF 00489791; Phosphodiesterase 5

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLIC GMP; PF 00489791; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; DRUG; PF-00489791; PHOSPHODIESTERASE V;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; MALE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; BLOOD PRESSURE MONITORING; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACEUTICAL PREPARATIONS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67049155295     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.132225     Document Type: Article

References (20)

1. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL. Cyclic nucleotide phosphodi-esterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol. 2003;64:533-546.
2. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res. 2007;19:139-148.
3. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res. 2007; 19:296-302.
4. Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep. 2006;8:345-351.
5. Guimaraes GV, d'Avila VM, Pires P, Bacal F, Stolf N, Bocchi E. Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients. Transplant Proc. 2007;39:3142-3149.
6. Patterson D, McInnes GT, Webster J, Mitchell MM, Macdonald TM. Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. Br J Clin Pharmacol. 2006;62:280-287.
7. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension. 2006;48:622-627.
8. Teloken PE, Mulhall JP. Impact of phosphodiesterase type 5 inhibitors on endothelial function. Rev Urol. 2008;10:26-30.
9. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens. 2008;26: 501-507.
10. Cheng J, Grande JP. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood). 2007;232:38-51.
11. Bednar MM. The role of sildenafil in the treatment of stroke. Curr Opin Inveslig Drugs. 2008;9:754-759.
12. Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 2006;1118:192-198.
13. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
14. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116: 238-248.
15. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006;316:654-661.
16. Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol. 2008;154:787-796.
17. Mochida H, Inoue H, Takagi M, Noto T, Yano K, Kikkawa K. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Eur J Pharmacol. 2002; 440:45-52.
18. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem. 2005;280: 12944-12955.
19. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res. 2003;92:595-597.
20. Muzaffar S, Shukla N, Srivastava A, Angelini GD, Jeremy JY. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol. 2005;146:109-117.